Hepatitis C Elimination
Policy Resources and Thought Leadership
HepVu
Launched in partnership with Emory University, HepVu.org provides users with visualized data, interactive maps, and educational resources that illustrate the hepatitis C (HCV) epidemic in the United States. Gilead is proud of our ongoing partnership with and commitment to HepVu’s mission of making data widely available, easily accessible and locally relevant to inform public health decision-making.
HepConnect
HepConnect is a five-year, multimillion-dollar initiative aimed at addressing the increase in HCV infections. In partnership with local organizations, the initiative will develop and implement evidence-based solutions to meet the needs of people most affected by the opioid crisis.
Race to Elimination
This report, published by the Boston Consulting Group in collaboration with expert advisers and key opinion leaders, assesses how European countries are progressing towards the elimination goal, recognizing policy barriers along with recommended priority policy actions that countries can take to achieve the elimination goal. It also reviews key population groups affected by HCV and shares effective, validated models of care built around the needs of these groups. The aim is to support policymakers identify international models of best practices to support elimination efforts in their own countries.
Value of Cure Infographic
This infographic sets out the real-world clinical and financial benefits that countries are starting to see from HCV cure, including reduction in HCV mortality, reduction in liver transplants due to HCV and reduction in HCV morbidity – along with associated cost savings. These real-world results demonstrate that an up-front investment in elimination programmes can yield short- and medium-term savings to health systems. See the infographic here.
HCV Elimination Factsheet
Gilead is committed to achieving the World Health Organization's targets of Hepatitis C elimination by 2030. This factsheet details the global status of progress towards elimination, including outlining some of the inequalities in HCV care and the steps Gilead is taking to reach the goal of HCV elimination by 2030. Read the factsheet here.
HCV Elimination Partnerships and Programs
We are committed to working together with researchers, non-governmental organizations, governments and the communities affected by the disease, in pursuit of elimination of HCV. These partnerships are helping to develop successful elimination models that can be scaled up and applied elsewhere. Take a look at some of the HCV elimination programs happening across the world.
Mobile Hepatitis Team, France
JAILFREE-C, Spain
TraP Hep C, Iceland
Project Arkhangai, Mongolia
COMMIT Grantee Video: EpaC Onlus, Italy
Global Access
Highlighting Gilead’s commitment to ensuring everyone has access to prevention and treatment medications, regardless of where they live or their economic status.
VISIT SITE
The content of this virtual hub is non-promotional and was created by Gilead Sciences.
© 2021 Gilead Sciences Inc., All Rights Reserved
Job code: IHQ-UNB-0820 Date of preparation: October 2021